371 related articles for article (PubMed ID: 29515516)
1. Cystic Fibrosis-Related Diabetes.
Kayani K; Mohammed R; Mohiaddin H
Front Endocrinol (Lausanne); 2018; 9():20. PubMed ID: 29515516
[TBL] [Abstract][Full Text] [Related]
2. Islet-intrinsic effects of CFTR mutation.
Koivula FNM; McClenaghan NH; Harper AGS; Kelly C
Diabetologia; 2016 Jul; 59(7):1350-1355. PubMed ID: 27033560
[TBL] [Abstract][Full Text] [Related]
3. The effect of cystic fibrosis transmembrane conductance regulator modulators on impaired glucose tolerance and cystic fibrosis related diabetes.
Hasan S; Khan MS; Lansang MC
J Clin Transl Endocrinol; 2022 Sep; 29():100301. PubMed ID: 35746945
[TBL] [Abstract][Full Text] [Related]
4. New Concepts in the Pathogenesis of Cystic Fibrosis-Related Diabetes.
Moheet A; Moran A
J Clin Endocrinol Metab; 2022 May; 107(6):1503-1509. PubMed ID: 35106591
[TBL] [Abstract][Full Text] [Related]
5. Cystic Fibrosis-Related Diabetes (CFRD): Overview of Associated Genetic Factors.
Iafusco F; Maione G; Rosanio FM; Mozzillo E; Franzese A; Tinto N
Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33810109
[TBL] [Abstract][Full Text] [Related]
6. The course of glucose intolerance in children with cystic fibrosis: a retrospective study - preliminary report.
Piechowiak K; Trippenbach-Dulska H; Walicka-Serzysko K
Dev Period Med; 2015; 19(1):80-91. PubMed ID: 26003073
[TBL] [Abstract][Full Text] [Related]
7. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients.
Kutney K; Donnola SB; Flask CA; Gubitosi-Klug R; O'Riordan M; McBennett K; Sferra TJ; Kaminski B
World J Hepatol; 2019 Dec; 11(12):761-772. PubMed ID: 31966908
[TBL] [Abstract][Full Text] [Related]
8. Advances in cystic fibrosis-related diabetes: Current status and future directions.
Lurquin F; Buysschaert M; Preumont V
Diabetes Metab Syndr; 2023 Nov; 17(11):102899. PubMed ID: 37939435
[TBL] [Abstract][Full Text] [Related]
9. Management of endocrine disease: Cystic fibrosis-related diabetes: novel pathogenic insights opening new therapeutic avenues.
Barrio R
Eur J Endocrinol; 2015 Apr; 172(4):R131-41. PubMed ID: 25336504
[TBL] [Abstract][Full Text] [Related]
10. Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes.
Putman MS; Norris AW; Hull RL; Rickels MR; Sussel L; Blackman SM; Chan CL; Ode KL; Daley T; Stecenko AA; Moran A; Helmick MJ; Cray S; Alvarez JA; Stallings VA; Tuggle KL; Clancy JP; Eggerman TL; Engelhardt JF; Kelly A
Diabetes Care; 2023 Jun; 46(6):1112-1123. PubMed ID: 37125948
[TBL] [Abstract][Full Text] [Related]
11. Cystic Fibrosis-Related Diabetes Workshop: Research Priorities Spanning Disease Pathophysiology, Diagnosis, and Outcomes.
Putman MS; Norris AW; Hull RL; Rickels MR; Sussel L; Blackman SM; Chan CL; Ode KL; Daley T; Stecenko AA; Moran A; Helmick MJ; Cray S; Alvarez JA; Stallings VA; Tuggle KL; Clancy JP; Eggerman TL; Engelhardt JF; Kelly A
Diabetes; 2023 Jun; 72(6):677-689. PubMed ID: 37125945
[TBL] [Abstract][Full Text] [Related]
12. Cystic fibrosis-related diabetes: The unmet need.
Pozo L; Bello F; Mendez Y; Surani S
World J Diabetes; 2020 Jun; 11(6):213-217. PubMed ID: 32547695
[TBL] [Abstract][Full Text] [Related]
13. Cystic fibrosis-related diabetes: an update on pathophysiology, diagnosis, and treatment.
Alves C; Della-Manna T; Albuquerque CTM
J Pediatr Endocrinol Metab; 2020 Jul; 33(7):835-843. PubMed ID: 32651985
[TBL] [Abstract][Full Text] [Related]
14. Cystic Fibrosis-Related Diabetes: Pathophysiology and Therapeutic Challenges.
Kelsey R; Manderson Koivula FN; McClenaghan NH; Kelly C
Clin Med Insights Endocrinol Diabetes; 2019; 12():1179551419851770. PubMed ID: 31191067
[TBL] [Abstract][Full Text] [Related]
15. Survival in a bad neighborhood: pancreatic islets in cystic fibrosis.
Norris AW; Ode KL; Merjaneh L; Sanda S; Yi Y; Sun X; Engelhardt JF; Hull RL
J Endocrinol; 2019 Feb; ():. PubMed ID: 30759072
[TBL] [Abstract][Full Text] [Related]
16. Understanding the Pancreatic Islet Microenvironment in Cystic Fibrosis and the Extrinsic Pathways Leading to Cystic Fibrosis Related Diabetes.
Al-Selwi Y; Shaw JA; Kattner N
Clin Med Insights Endocrinol Diabetes; 2021; 14():11795514211048813. PubMed ID: 34675737
[TBL] [Abstract][Full Text] [Related]
17. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
18. Cystic Fibrosis Related Diabetes - An Update.
F F; Mj W; D N
QJM; 2020 Aug; ():. PubMed ID: 32821951
[TBL] [Abstract][Full Text] [Related]
19. Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure.
Hull RL; Gibson RL; McNamara S; Deutsch GH; Fligner CL; Frevert CW; Ramsey BW; Sanda S
Diabetes Care; 2018 Apr; 41(4):823-830. PubMed ID: 29437698
[TBL] [Abstract][Full Text] [Related]
20. The role of modulators in cystic fibrosis related diabetes.
Merjaneh L; Hasan S; Kasim N; Ode KL
J Clin Transl Endocrinol; 2022 Mar; 27():100286. PubMed ID: 34917484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
